

# Kinga Kamińska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3046498/publications.pdf>

Version: 2024-02-01

17  
papers

188  
citations

1039406

9  
h-index

1125271

13  
g-index

18  
all docs

18  
docs citations

18  
times ranked

239  
citing authors

#	ARTICLE	IF	CITATIONS
1	N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2125.	1.8	10
2	Glutathione Deficiency during Early Postnatal Development Causes Schizophrenia-Like Symptoms and a Reduction in BDNF Levels in the Cortex and Hippocampus of Adult Spragueâ€Dawley Rats. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6171.	1.8	13
3	Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Spragueâ€Dawley rats exposed to glutathione deficit during early postnatal development of the brain. <i>Pharmacological Reports</i> , 2021, 73, 1712-1723.	1.5	3
4	Evaluation of Cysteine Metabolism in the Rat Liver and Kidney Following Intravenous Cocaine Administration and Abstinence. <i>Antioxidants</i> , 2021, 10, 74.	2.2	2
5	Effects of L-DOPA on Gene Expression in the Frontal Cortex of Rats with Unilateral Lesions of Midbrain Dopaminergic Neurons. <i>ENeuro</i> , 2021, 8, .	0.9	0
6	Effects of L-DOPA on Gene Expression in the Frontal Cortex of Rats with Unilateral Lesions of Midbrain Dopaminergic Neurons. <i>ENeuro</i> , 2021, 8, ENEURO.0234-20.2020.	0.9	0
7	Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex. <i>Behavioural Brain Research</i> , 2020, 393, 112769.	1.2	15
8	Alterations in the Antioxidant Enzyme Activities in the Neurodevelopmental Rat Model of Schizophrenia Induced by Glutathione Deficiency during Early Postnatal Life. <i>Antioxidants</i> , 2020, 9, 538.	2.2	19
9	Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats. <i>Pharmacological Reports</i> , 2019, 71, 768-773.	1.5	10
10	Glutathione Deficiency and Alterations in the Sulfur Amino Acid Homeostasis during Early Postnatal Development as Potential Triggering Factors for Schizophrenia-Like Behavior in Adult Rats. <i>Molecules</i> , 2019, 24, 4253.	1.7	15
11	Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease. <i>Neurochemistry International</i> , 2018, 121, 125-139.	1.9	7
12	Depressive-like neurochemical and behavioral markers of Parkinsonâ€™s disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle. <i>Pharmacological Reports</i> , 2017, 69, 985-994.	1.5	33
13	The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA. <i>Neuroscience</i> , 2017, 340, 308-318.	1.1	13
14	Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats. <i>Pharmacological Reports</i> , 2017, 69, 29-35.	1.5	2
15	Decreased behavioral response to intranigally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: Comparison to the classical neurotoxin 6-OHDA. <i>Behavioural Brain Research</i> , 2015, 283, 203-214.	1.2	9
16	Chronic l-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra. <i>Behavioural Brain Research</i> , 2014, 261, 79-88.	1.2	19
17	Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA. <i>Neurochemistry International</i> , 2013, 63, 790-804.	1.9	18